Kearns-Sayre syndrome presenting as isolated growth failure

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Holloman, Conisha Mone ^a,b   Wolfe, Lynne A ^a   Gahl, William A ^a   Boerkoel, Cornelius F ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; CARNITINE; CREATINE; GROWTH HORMONE; LACTIC ACID; SELENIUM; TESTOSTERONE; THIOCTIC ACID; UBIQUINONE DERIVATIVE; ZINC DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ATAXIA; BODY HEIGHT; BODY MASS; BONE AGE; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CEREBROVASCULAR ACCIDENT; CHILD; CONSTIPATION; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIVERGENT STRABISMUS; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEMALE; FLATFOOT; GAIT DISORDER; GROWTH DISORDER; HEART ATRIUM PACEMAKER; HEART RIGHT BUNDLE BRANCH BLOCK; HEAT INTOLERANCE; HORMONAL THERAPY; HUMAN; KEARNS SAYRE SYNDROME; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MEMORY DISORDER; MUSCLE WEAKNESS; OPHTHALMOPLEGIA; OPTIC NERVE ATROPHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PTOSIS; RETINA DEGENERATION; RETINITIS PIGMENTOSA; SCHOOL CHILD; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISUAL SYSTEM EXAMINATION; WEIGHT GAIN;

EID: 84876591508     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007272     Document Type: Article

References (19)

1. Goulet O. Growth faltering: setting the scene. Eur J Clin Nutr 2010;64:S2-4.
2. Cole SZ, Lanham JS. Failure to thrive: an update. Am Fam Physician 2011;83:829-34.
3. Finsterer J. Mitochondriopathies. Eur J Neurol 2004;11:163-86. (Pubitemid 38373033)
4. Han JC, Balagopal P, Sweeten S, et al. Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J Clin Endocrinol Metab 2006;91:2081-6. (Pubitemid 43854986)
5. Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre Syndrome. Clin Endocrinol (Oxf) 1992;37:97-103.
6. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008;63:35-9. (Pubitemid 351240549)
7. Davis RL, Sue CM. The genetics of mitochondrial disease. Semin Neurol 2011;31:519-30.
8. Yau EK, Chan KY, Au KM, et al. A novel mitochondrial DNA deletion in a Chinese girl with Kearns-Sayre syndrome. Hong Kong Med J 2009;15:374-7.
9. López-Gallardo E, López-Pérez MJ, Montoya J, et al. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion 2009;9:314-17.
10. DelCarlo M, Loeser RF. Chondrocyte cell death mediated by reactive oxygen species-dependent activation of PKC-betal. Am J Cell Physiol 2006;290:C802-11.
11. Quade A, Zierz S, Klingmuller D. Endocrine abnormalities in mitochondrial myopathy with external ophthalmoplegia. Clin Investig 1992;70:396-402.
12. Egger J, Lake BD, Wilson J. Mitochondrial cytopathy. A multisystem disorder with ragged red fibres on muscle biopsy. Arch Dis Child 1981;56:741-52. (Pubitemid 11031679)
13. Burns EC, Preece MA, Cameron N, et al. Growth hormone deficiency in mitochondrial cytopathy. Acta Paediatr Scand 1982;71:693-7. (Pubitemid 12120381)
14. Romano S, Samara D, Crosnier H, et al. Variable outcome of growth hormone administration in respiratory chain deficiency. Mol Genet Metab 2008;93:195-9.
15. Goldstein A, Wolfe LA. The elusive magic pill: finding effective therapies. Neurotherapeutics 2013; Epub ahead of print: PMID: 23355364.
16. Tews D, Wabitsch M. Renaissance of brown adipose tissue. Horm Res Paediatr 2011;75:231-9.
17. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev 2008;60:1561-7.
18. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35:235-42.
19. Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008;5:558-68.